Market Cap (In USD)
894.79 Million
Revenue (In USD)
-
Net Income (In USD)
-142.18 Million
Avg. Volume
706.47 Thousand
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 7.0-16.63
- PE
- -
- EPS
- -
- Beta Value
- 0.978
- ISIN
- US2825591033
- CUSIP
- 282559103
- CIK
- 1785173
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Rohan Palekar
- Employee Count
- -
- Website
- https://www.89bio.com
- Ipo Date
- 2019-11-11
- Details
- 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.
More Stocks
-
AAJ
-
TIRTPLSTIRTH PLASTIC LTD.
TIRTPLS
-
002058
-
216080JETEMA, Co., Ltd.
216080
-
0255
-
ZPRS
-
9551Knowledge Tower
9551
-
OPRT